Thomas P. Blackburn
Direttore/Membro del Consiglio presso Umecrine Cognition AB
Profilo
Thomas P.
Blackburn is currently the Director at Umecrine Cognition AB since 2017.
Previously, he held positions such as Acting CEO & Vice President-Clinical Development at Helicon Therapeutics, Senior Director-Medical Affairs at Lundbeck Research USA, Director at GSK Plc, and Vice President-Drug Development Operations at Synaptics, Inc. Blackburn received his undergraduate and doctorate degrees from The University of Manchester.
Posizioni attive di Thomas P. Blackburn
| Società | Posizione | Inizio |
|---|---|---|
Umecrine Cognition AB
 Umecrine Cognition AB Pharmaceuticals: MajorHealth Technology Umecrine Cognition AB develops pharmaceuticals against neurological disorders in the central nervous system. The firm focuses on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. The company was founded by Torbjörn Bäckström in 2006 and is headquartered in Solna, Sweden. | Direttore/Membro del Consiglio | 05/09/2017 |
Precedenti posizioni note di Thomas P. Blackburn
| Società | Posizione | Fine |
|---|---|---|
| GSK PLC | Direttore/Membro del Consiglio | - |
Lundbeck Research USA, Inc.
 Lundbeck Research USA, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Research USA, Inc. develops pharmaceutical products and information to the medical community. The firm engages in the drug discovery aimed at treating central nervous system diseases by designing small molecule therapeutics. The company was founded in 1990 and is headquartered in Paramus, NJ. | Direttore Tecnico/Scientifico/R&S | - |
| SYNAPTICS INCORPORATED | Direttore operativo | - |
Helicon Therapeutics, Inc.
 Helicon Therapeutics, Inc. BiotechnologyHealth Technology Helicon Therapeutics, Inc. developed drugs and other therapeutic products. It products include HT-0712 and HT-2157 which are used for the treatment of memory impairment. The company was founded in July 1997 and was headquartered in San Diego, CA. | Presidente | - |
Formazione di Thomas P. Blackburn
| The University of Manchester | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| SYNAPTICS INCORPORATED | Electronic Technology |
| GSK PLC | Health Technology |
| Aziende private | 3 |
|---|---|
Helicon Therapeutics, Inc.
Helicon Therapeutics, Inc. BiotechnologyHealth Technology Helicon Therapeutics, Inc. developed drugs and other therapeutic products. It products include HT-0712 and HT-2157 which are used for the treatment of memory impairment. The company was founded in July 1997 and was headquartered in San Diego, CA. | Health Technology |
Lundbeck Research USA, Inc.
Lundbeck Research USA, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Research USA, Inc. develops pharmaceutical products and information to the medical community. The firm engages in the drug discovery aimed at treating central nervous system diseases by designing small molecule therapeutics. The company was founded in 1990 and is headquartered in Paramus, NJ. | Health Technology |
Umecrine Cognition AB
Umecrine Cognition AB Pharmaceuticals: MajorHealth Technology Umecrine Cognition AB develops pharmaceuticals against neurological disorders in the central nervous system. The firm focuses on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. The company was founded by Torbjörn Bäckström in 2006 and is headquartered in Solna, Sweden. | Health Technology |
- Borsa valori
- Insiders
- Thomas P. Blackburn
